UPMC has long been a leader in cardiovascular care, with a rich history in clinical research and innovation.
At the UPMC Heart and Vascular Institute, our patients benefit from having access to some of the most current and promising procedures and medications.
Our expertise in diagnosing and treating a large and diverse volume of patients, along with our commitment to advancing scientific discovery, has helped us develop a very strong catalog of research on heart and vascular diseases.
Specifically, in Central Pa., our team of experts are currently engaged in the following trials:
AFFIRM
Principal Investigator: William Bachinsky, MD
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation.
Primary Coordinator: Joanna Miller, RN millerjl30@upmc.edu
ALLAY
Principal Investigator: Roberto Hodara, MD
This is a prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.
Primary Coordinator: Kathy Retzlaff, RN
retzlaffkl@upmc.edu
ALLIANCE
Principal investigator: David Loran, MD
The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS).
Research Nurse: Brittany Mashuda, RN mashudabd@upmc.edu
CATALYST
Principal investigator: Hemal Gada, MD
The purpose of the study is to analyze Atrial Fibrillation patients comparing left atrial appendage occlusion therapy to non-vitamin K antagonist oral anticoagulants. Prospective, randomized, controlled, unblinded, multicenter clinical trial of the Amplatzer Amulet device in patients with non-Valvular atrial fibrillation who are increased risk for cardioembolic events.
Research nurse: Anita Todd, RN toddag@upmc.edu
ENVISION
Principal Investigator: Hemal Gada, MD
The objective of ENVISION is to evaluate the safety and effectiveness of the Navitor Transcatheter Aortic Valve Implantation (TAVI) System for treating patients with symptomatic, severe native aortic stenosis who are considered intermediate or low risk for surgical mortality.
Primary Coordinator: Matthew Rutt, RN ruttmd4@upmc.edu
EVOID-AS
Principal Investigator: Roberto Hodara, MD
This is an adaptive Phase 2/3 multicenter, double-blind, placebo-controlled, randomized, parallel, 3 arm study to evaluate the efficacy and safety of DA-1229 compared to placebo in patients with calcific aortic valve disease with mild to moderate aortic stenosis.
Primary Coordinator: Amy Worley, RN worleyas@upmc.edu
Evolut Expand II
Principal Investigators: Hemal Gada, MD and Atizazul Mansoor, MD
The study is designed to demonstrate the safety and effectiveness of the Medtronic TAVR system to include patients with moderate, symptomatic aortic stenosis.
Primary Coordinator: Olivia Vehabovic, RN vehabovicoc@upmc.edu
REPAIR MR Study
Principal investigator: Mubashir Mumtaz, MD
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Research nurse: Anita Todd, RN toddag@upmc.edu
ShortCut Study
Principal investigator: Hemal Gada, MD
The purpose of this study is to assess the safety and effectiveness of the ShortCut™ device for splitting bioprosthetic aortic valve leaflets, and to demonstrate coronary artery ostia patency following leaflet split, in patients who are at risk for TAVR-induced coronary artery ostium obstruction following a ViV procedure.
Research nurse: Brittany Mashuda, RN mashudabd@upmc.edu
Need more information?
Phone: 717-731-0101
Request Information